stars 1 stars 2 stars 3

Tetraneuron is a drug discovery company, focused on the development of a disruptive gene therapy for Alzheimer’s Disease (AD) and an Early Biomarker for this neurodegenerative condition.

TETRANEURON Questions

The TETRANEURON annual revenue was $3 million in 2026.

Angel Lucio is the CEO of TETRANEURON.

9 people are employed at TETRANEURON.

The NAICS codes for TETRANEURON are [54, 541].

The SIC codes for TETRANEURON are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users